LucentLucent Intel
Sign in
MRNA$145.13+8.9%ZYME$28.67+7.9%IOVA$8.29-7.8%TGTX$54.27+7.3%SMMT$13.16+5.9%EDIT$3.11+5.8%BEAM$29.76+4.8%PRTA$9.45+4.7%MRVI$8.64+4.2%ARVN$9.37+3.8%VERA$32.27+3.2%NTLA$12.84+3.2%MRNA$145.13+8.9%ZYME$28.67+7.9%IOVA$8.29-7.8%TGTX$54.27+7.3%SMMT$13.16+5.9%EDIT$3.11+5.8%BEAM$29.76+4.8%PRTA$9.45+4.7%MRVI$8.64+4.2%ARVN$9.37+3.8%VERA$32.27+3.2%NTLA$12.84+3.2%
Weekly brief·2026-08-17

BMY and CAPR face FDA decision points as PFE and MRK dates look stale after early approvals

Bristol-Myers Squibb and Capricor carry the live FDA stakes in the period, with BMY's iberdomide filing focused on an MRD-based pathway and CAPR's deramiocel review shadowed by a prior 3–9 AdCom vote. Pfizer and Merck also appear on the calendar, but posts in the substrate indicate their shared Keytruda plus Padcev action was approved early, making those dates stale rather than fresh catalysts.

Read the full brief →

Catalysts · Next 3 weeks

What’s on the calendar

$CAPRtodayAug 22, 2026
PDUFA·PDUFA: CAPR — target action date
$RAREtomorrowAug 23, 2026
PDUFA·PDUFA: DTX401 — GSD1a
$GILDin 5 daysAug 27, 2026
PDUFA·PDUFA: BIC/LEN — treatment of HIV

Top biopharma news

Live feed

What KOLs and the press are saying

  • KOL$GILD
    @PDUFA_Pulse·$GILD / BIC-LEN is the cleanest FDA setup next week. In ARTISTRY-1, HIV RNA ≥50 copies/mL at week 48: BIC/LEN 0.8% Complex regimen 1.1% No emergent resistance. Aug. 27 is less about efficacy failure than exactly who FDA lets switch.
    8h ago
  • KOL$CAPR
    @PDUFA_Pulse·Tomorrow’s $CAPR date is not a clean approve/CRL binary. Capricor says FDA is willing to review a 24-month HOPE-3 amendment focused on upper-limb function and extend the review. The live question is now what gets filed—and how FDA treats it.
    14h ago
  • news$CAPR
    BioPharma Dive·Shareholder pressures Capricor; Lilly dives deeper into vaccines
    17h ago
  • news$GILD
    ClinicalTrials.gov·CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
    1d ago
  • news$RARE
    BioPharma Dive·Ultragenyx, after setbacks, nabs first gene therapy approval
    1d ago
  • news$CAPR
    Seeking Alpha — Biopharma·Capricor slips on potential Deramiocel rejection (CAPR:NASDAQ) - Seeking Alpha
    1d ago
  • news$RARE
    STAT News·STAT+: FDA approves Ultragenyx gene therapy
    1d ago
  • KOL$RARE
    @PDUFA_Pulse·$RARE / DTX401 may be the cleanest gene-therapy test on the near-term board. Phase 3: ~60% reduction in daily cornstarch burden at 96 weeks. But Ultragenyx built the filing to address CMC/facility lessons from the prior UX111 CRL. Aug. 23 tests whether that remediation closed.
    3d ago
  • KOL$RARE
    @PDUFA_Pulse·$RARE’s DTX401 PDUFA lands Sunday, Aug. 23. If no press release appears Sunday, that is not evidence of a delay or CRL. $REPL just showed why weekend clocks need discipline. The real questions are clinical meaningfulness + CMC/inspection closeout. Keep it live until disclosed.
    3d ago
  • KOL$GILD
    @PDUFA_Pulse·$GILD is the cleanest setup on the board: 89% PoA. Two positive Phase 3 noninferiority switch trials support BIC/LEN. The residual question is label scope: who can switch, how resistance history is handled, and whether the final language preserves simplification value. Today's
    4d ago
  • KOL$CAPR
    @PDUFA_Pulse·$CAPR’s Aug. 22 date is no longer the main event. A planned amendment shifts the case toward upper-limb function, and FDA is expected to extend the clock after receipt. The live question: can a reframed indication overcome the evidence dispute? PoA: 10%.
    4d ago
  • KOL$GILD
    @PDUFA_Pulse·Seven live FDA clocks, Aug 22–Sep 11: $CAPR → $RARE → $JAZZ → $GILD → PharmaEssentia → Advicenne → Telix Same calendar. Different failure modes. The useful question is not just approve/CRL. It is what can break each filing. Full board: https://t.co/O7sqidTldC
    4d ago
  • KOL$RARE
    @PDUFA_Pulse·Seven live FDA clocks, Aug 22–Sep 11: $CAPR → $RARE → $JAZZ → $GILD → PharmaEssentia → Advicenne → Telix Same calendar. Different failure modes. The useful question is not just approve/CRL. It is what can break each filing. Full board: https://t.co/O7sqidTldC
    4d ago
  • KOL$CAPR
    @PDUFA_Pulse·Seven live FDA clocks, Aug 22–Sep 11: $CAPR → $RARE → $JAZZ → $GILD → PharmaEssentia → Advicenne → Telix Same calendar. Different failure modes. The useful question is not just approve/CRL. It is what can break each filing. Full board: https://t.co/O7sqidTldC
    4d ago
  • news$GILD
    ClinicalTrials.gov·GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
    5d ago

What is Lucent

Catalyst-anchored biopharma intelligence.

Lucent is a biopharma intelligence platform. It monitors X, SEC filings, clinical trial disclosures, and analyst commentary — anchored to the catalyst calendar — and publishes a weekly synthesis.

Signal extraction

Every analyst post, FDA filing, and earnings call parsed and scored in minutes.

Catalyst calendar

1,200+ tracked events: PDUFAs, AdComs, readouts, earnings, conferences.

Cross-trial efficacy

Normalized endpoints across competing drug programs. Compare apples to apples.

Read-through alerts

Watch one ticker. Get alerted when something hits a related drug or peer.

See Lucent chat

Ask a real question. Get a cited answer.

Question
How does Rezdiffra's real-world launch trajectory compare to expectations?

Bottom line: Rezdiffra's launch appears at least in line with, and likely ahead of, prior expectations on the commercial metrics Lucent surfaces. The platform's compiled view labels execution "on track," and the freshest primary-source update available says Q1 2026 net sales reached $311.3M, with >42,250 active patients and patient count up 2.5x vs 1Q25. That is consistent with a launch that has moved beyond a cautious specialty rollout into broad physician adoption.

Why I say that

  • Lucent's Rezdiffra wiki explicitly characterizes commercial execution as strong: trailing-12-month net sales exceeded $1.1B, demand remained strong, and management framed the launch as tracking "in line with or exceeding" best-in-class specialty launches.
  • The wiki is recent — compiled 2026-06-02 — so this is not an obviously stale take.
  • The platform was thin on recent launch news/posts, so I checked the web. Madrigal's May 6, 2026 release says Rezdiffra had $311.3M Q1 2026 sales and >42,250 patients on therapy, while reiterating confidence in "robust growth expectations" for 2026.
  • An external prescription-trends paper supports the idea that uptake has been meaningful in the real world, though it covers only through Nov. 2025 and is based on pharmacy-fill data rather than full net-sales economics.

Footnotes

  1. Resmetirom — Lucent wiki (compiled 2026-06-02)

  2. Madrigal Pharmaceuticals — Q1 2026 earnings release

  3. National trends in resmetirom prescriptions for MASH — Clin Mol Hepatol

Continue the answer in chat →

Ask ChatGPT the same question and you’ll get: Rezdiffra had a strong initial launch as the first approved MASH drug and analysts were generally positive on uptake. For specific quarterly sales figures or the latest patient counts, I'd recommend checking Madrigal's investor relations page or a recent earnings summary.

Hit rate85.7%· N=788
Tracked X accounts23
Ticker wikis123
Drug wikis139

Pilot launching this quarter

We’re inviting a small group of biopharma traders to the alpha. Tell us about your workflow and we’ll be in touch.